1.32
0.16 (13.79%)
| Previous Close | 1.16 |
| Open | 1.17 |
| Volume | 8,841,631 |
| Avg. Volume (3M) | 4,222,219 |
| Market Cap | 412,242,272 |
| Price / Sales | 73.02 |
| Price / Book | 117.57 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2025 |
| Operating Margin (TTM) | -979.14% |
| Diluted EPS (TTM) | -0.200 |
| Quarterly Revenue Growth (YOY) | 46.10% |
| Total Debt/Equity (MRQ) | 199.97% |
| Current Ratio (MRQ) | 2.60 |
| Operating Cash Flow (TTM) | -50.90 M |
| Levered Free Cash Flow (TTM) | -27.58 M |
| Return on Assets (TTM) | -61.33% |
| Return on Equity (TTM) | -248.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ocugen, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA"). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.60% |
| % Held by Institutions | 26.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summittx Capital, L.P. | 30 Jun 2025 | 639,200 |
| 52 Weeks Range | ||
| Median | 7.00 (430.30%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 19 Sep 2025 | 7.00 (430.30%) | Buy | 1.34 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Nov 2025 | Announcement | Ocugen Provides Business Update with Third Quarter 2025 Financial Results |
| 23 Oct 2025 | Announcement | Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results |
| 02 Oct 2025 | Announcement | Ocugen to Present at Industry and Investor Conferences in October 2025 |
| 15 Sep 2025 | Announcement | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea |
| 02 Sep 2025 | Announcement | Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |